Deerfield Management COGT Position
Active13-Fund ConvergenceDeerfield Management trimmed their position in Cogent Biosciences Inc. (COGT) in Q4 2025, holding $321.2M worth of shares across 9,043,903 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
COGT is a convergence signal: 13 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Bezuclastinib in combination with sunitinib in 77 days (Jun 30, 2026), making the timing of Deerfield's position particularly relevant.
Short interest stands at 10.7% of float with 8.4 days to cover, indicating significant bearish positioning against Deerfield's long thesis.
About Cogent Biosciences Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
10.7%
8.4 days to cover
Deerfield Management COGT Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 9,043,903 | -9,215 | $321.2M |
| Q3 2025 | Increased | 9,053,118 | +6,412,903 | $130.0M |
| Q2 2025 | Increased | 2,640,215 | +6,353 | $19.0M |
| Q1 2025 | Increased | 2,633,862 | +2,862 | $15.8M |
| Q4 2024 | Decreased | 2,631,000 | -1,113,263 | $20.5M |
| Q3 2024 | Held | 3,744,263 | — | $40.4M |
| Q2 2024 | Increased | 3,744,263 | +2,209,918 | $31.6M |
| Q1 2024 | Increased | 1,534,345 | +445,000 | $10.3M |
| Q4 2023 | Held | 1,089,345 | — | $6.4M |
| Q3 2023 | Decreased | 1,089,345 | -2,277,000 | $10.6M |
| Q2 2023 | Increased | 3,366,345 | +400,000 | $39.9M |
| Q1 2023 | New | 2,966,345 | +2,966,345 | $32.0M |
Frequently Asked Questions
Does Deerfield Management own COGT?
Yes. As of Q4 2025, Deerfield Management holds 9,043,903 shares of Cogent Biosciences Inc. (COGT) valued at $321.2M. This data comes from their SEC 13F filing.
How many hedge funds own COGT?
13 specialist biotech hedge funds currently hold COGT, including RTW Investments, Commodore Capital, RA Capital Management and 9 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy COGT?
Deerfield Management's position in COGT was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's COGT position increasing or decreasing?
Deerfield Management trimmed their COGT position in the most recent quarter, reducing by 9,215 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
COGTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →